Oct 15, 2021
U.S. FDA declines to approve Revance's frown-line treatment By Reuters
U.S. FDA declines to approve Revance’s frown-line treatment By Reuters
© Reuters. FILE PHOTO: Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File Photo (Reuters) – Revance Therapeutics (NASDAQ:) Inc said on Friday the U.S. Food and Drug Administration had declined to approve its long-acting injectable drug to treat moderate to severe frown lines, sending its shares…
View On WordPress